Tipeptidine as adjuvant therapy in children with ADHD
Phase 3
Recruiting
- Conditions
- Disturbance of activity and attention.Attention-deficit hyperactivity disorder, combined type
- Registration Number
- IRCT20090117001556N108
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Diagnosis of ADHD based on DSM-5
Age between 6-17 years old
Exclusion Criteria
Intellectual disability
Presence of any psychiatric disorders except for ODD
Receiving any neuroleptic during the last 6 months
Weight less than 13.5 kg
History of allergy to Tipeptidine or Ritaline
Presence of any neurologic disease and any condition requiring surgery
Uncontrolled seizures
Systolic blood pressure more than 125 mm Hg; resting pulse rate less than 60/minute or more than 115/minute
Severe medical disease
Receiving any medication or supplement for treatment ADHD
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method